NPPA outcomes data for ceftolozane and tazobactam

OIA response

19 April 2019 

Dear [name and contact details withheld]


Thank you for your request dated 1 April 2021 under the Official Information Act 1982 (OIA) for information relating to Named Patient Pharmaceutical Assessment (NPPA) outcomes.

On 1 April 2021, you requested an update of the current NPPA outcome data available on the PHARMAC website:> Medicine funding and supply > Make an application > NPPA applications > NPPA outcome data.

We responded to advise that our NPPA team is planning to update the published information with the 2020 calendar year data in the next couple months and asked if you would be comfortable waiting until the data is made available online. 

On 14 April 2021, you asked:

Is it faster if I just request it for one particular product then?
If so, the product I am interested in is ceftolozane and tazobactam.

Please find our response to your request for information below.

NPPA 2020 outcomes

Within the 2020 calendar year, three NPPA applications for ceftolozane/tazobactam were submitted. 

Of the three applications submitted, two were approved by PHARMAC and one was approved via the DHB rapid assessment process. 

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this. 

Yours sincerely

Rachel Read
Manager, Policy and Government Services